Cellulitis

Cellulitis – High-Yield Study Guide for Medical Students

Definition

Cellulitis is an acute, diffuse, spreading bacterial infection of the dermis and subcutaneous tissues characterized by localized erythema, warmth, swelling, and tenderness, usually without abscess formation. It most commonly affects the lower extremities and is typically caused by β-hemolytic streptococci (especially group A) and Staphylococcus aureus, including MRSA in certain settings.

Epidemiology

Cellulitis is a common cause of skin and soft tissue infection presentations in both outpatient and inpatient settings. Incidence increases with age and is higher in patients with comorbidities such as diabetes, chronic venous insufficiency, chronic edema/lymphedema, obesity, and immunosuppression. Recurrent cellulitis is frequent in patients with persistent predisposing factors such as tinea pedis, chronic leg edema, or skin barrier disruption.

Pathophysiology

Cellulitis results from bacterial entry through a breach in the skin barrier (e.g., fissures, ulcers, trauma, insect bites, tinea pedis) followed by spread through the dermis and subcutaneous tissue. β-hemolytic streptococci produce enzymes (e.g., streptokinase, hyaluronidase, DNases) that facilitate tissue invasion and spread, whereas Staphylococcus aureus is more often associated with purulent foci and abscess formation.

The host response involves activation of innate immunity, recruitment of neutrophils, and release of inflammatory mediators, producing the classic signs of inflammation. In severe cases or in compromised hosts, bacterial toxins and systemic inflammatory responses can lead to systemic toxicity and sepsis, with potential microcirculatory dysfunction and impaired tissue perfusion, especially in critically ill patients. [1](https://pubmed.ncbi.nlm.nih.gov/27885969/)

Clinical Presentation

Typical cellulitis presents as an acutely developing, painful, erythematous area of skin with local and sometimes systemic features.

• Local findings
  • Diffuse erythema with poorly demarcated borders (in contrast to sharply demarcated erysipelas)
  • Warmth and swelling of the affected area
  • Tenderness to palpation; skin may feel indurated
  • Possible regional lymphangitis and tender regional lymphadenopathy
  • Overlying skin may show fissures, ulcers, interdigital maceration, or trauma as portals of entry
• Systemic features
  • Fever, chills, malaise
  • Leukocytosis on laboratory evaluation
  • Signs of sepsis (tachycardia, hypotension, altered mental status) in severe cases

Lower extremity cellulitis is most common, but upper extremities, face, and trunk can be involved. Recurrent episodes often occur in the same limb, especially in the presence of chronic edema or venous disease.

Important Differentials

Several conditions mimic cellulitis, and distinguishing them is crucial to avoid misdiagnosis and unnecessary antibiotics.

• Erysipelas: More superficial infection with sharply demarcated, raised borders, often on the face or lower limbs; usually due to group A streptococcus.
• Abscess: Fluctuant, localized collection of pus; usually requires incision and drainage.
• Necrotizing soft tissue infection: Severe pain out of proportion to exam, rapidly progressive erythema, bullae, skin necrosis, crepitus, systemic toxicity; requires emergent surgical evaluation.
• Deep vein thrombosis: Unilateral leg swelling and pain; usually lacks erythema and warmth to the same degree; no portal of entry; consider duplex ultrasound in unclear cases.
• Stasis dermatitis / chronic venous insufficiency: Bilateral, chronic erythema and edema with hyperpigmentation, scaling, and pruritus; often non-tender and not accompanied by systemic signs.
• Contact dermatitis, gout, pseudogout, acute inflammatory arthritis: May mimic cellulitis but have distinct joint involvement or exposure history.

Diagnosis

Cellulitis is primarily a clinical diagnosis based on history and physical examination. No single laboratory or imaging test is diagnostic, but they can support assessment of severity and alternative diagnoses.

• History
  • Onset and progression of erythema, pain, and swelling
  • History of trauma, insect bite, animal or human bite, injection drug use, surgery, ulcers, tinea pedis, or other skin conditions
  • Comorbidities: diabetes, peripheral vascular disease, venous insufficiency, lymphedema, immunosuppression
  • Previous episodes of cellulitis or MRSA colonization
• Physical exam
  • Careful inspection of the affected area and search for portals of entry
  • Assessment of extent of erythema; marking borders is helpful for monitoring
  • Evaluation for fluctuance or purulence suggesting abscess
  • Assessment for features concerning for necrotizing infection (disproportionate pain, bullae, necrosis, crepitus)
• Laboratory tests
  • Complete blood count: leukocytosis is common but nonspecific
  • C-reactive protein / ESR: supportive of inflammation; may be used for trend monitoring
  • Blood cultures: generally low yield but recommended in severe infection, systemic toxicity, immunocompromised states, or unusual exposures
  • Wound or abscess cultures: if purulence is present; helpful for tailoring therapy
• Imaging
  • Ultrasound: useful to detect underlying abscess, foreign body, or DVT in the differential; point-of-care ultrasound is frequently used in emergency settings. [3](https://europepmc.org/article/MED/41745693)
  • CT/MRI: reserved for suspected deep space infection, necrotizing fasciitis, or when diagnosis remains uncertain.

Microbiology and Risk-Based Considerations

The causative organisms depend on host factors, anatomic site, and exposure history.

• Typical cellulitis (non-purulent): β-hemolytic streptococci (groups A, B, C, G).
• Purulent cellulitis and abscess: Staphylococcus aureus, including community-acquired MRSA.
• Diabetic foot infections, chronic ulcers: Often polymicrobial including gram-positive cocci, gram-negative rods, and anaerobes.
• Animal bites: Pasteurella multocida, Capnocytophaga canimorsus, anaerobes, staphylococci, streptococci.
• Human bites: Oral flora including streptococci, staphylococci, anaerobes, and Eikenella corrodens.
• Water exposure
  • Freshwater: Aeromonas species.
  • Saltwater: Vibrio vulnificus (can be rapidly progressive).

Management

Management is based on severity, presence of purulence, patient comorbidities, and risk factors for specific pathogens. Key components include appropriate antimicrobial therapy, identification and control of predisposing factors, and supportive care.

General Principles

• Assess severity and systemic involvement: mild (localized), moderate (systemic features), severe (hemodynamic instability, immunocompromise, rapidly progressive infection).
• Differentiate non-purulent vs purulent cellulitis, as this guides empiric coverage (streptococci vs MRSA).
• Identify risk factors for MRSA (previous MRSA infection/colonization, recent hospitalization or antibiotics, injection drug use, close-contact outbreaks).
• Evaluate for deep infection or necrotizing fasciitis when red flags are present.

Empiric Antibiotic Therapy (Adults – examples; always adjust to local resistance patterns)

Mild non-purulent cellulitis (outpatient, no systemic signs) – target β-hemolytic streptococci; staphylococcal coverage often included:

• Oral options
  • Cephalexin 500 mg PO every 6 hours
  • Dicloxacillin 500 mg PO every 6 hours
  • Clindamycin 300–450 mg PO every 6–8 hours (useful if penicillin-allergic; covers streptococci and many MRSA strains depending on local susceptibility)

Mild cellulitis with MRSA risk or purulent infection – include MRSA-active agents:

• Oral options
  • Trimethoprim-sulfamethoxazole (TMP-SMX) 1–2 DS tablets PO every 12 hours (often combined with a β-lactam, e.g., cephalexin, to ensure adequate streptococcal coverage)
  • Doxycycline 100 mg PO every 12 hours (also usually combined with a β-lactam for streptococcal coverage)
  • Clindamycin 300–450 mg PO every 6–8 hours (monotherapy if local resistance is low)

Moderate to severe cellulitis – hospitalization and IV therapy are generally indicated for systemic signs, rapid progression, comorbidities, or failure of oral therapy.

• Non-purulent cellulitis without MRSA risk
  • Cefazolin 1–2 g IV every 8 hours
  • Nafcillin or oxacillin 1–2 g IV every 4 hours
• With MRSA risk or purulent/severe infection
  • Vancomycin IV (dose based on weight and renal function; monitor troughs per institutional protocol)
  • Alternative agents depending on severity and susceptibility: linezolid, daptomycin, or ceftaroline (usually specialist-guided)
• Special exposure scenarios
  • Animal/human bites: amoxicillin-clavulanate PO or ampicillin-sulbactam IV to cover oral flora and anaerobes.
  • Freshwater exposures: fluoroquinolone (e.g., ciprofloxacin) plus appropriate gram-positive coverage.
  • Saltwater exposures: doxycycline plus a third-generation cephalosporin (e.g., ceftazidime) for Vibrio coverage.

Duration of therapy is typically 5–7 days for uncomplicated cases, extended if the clinical response is slow or if deep involvement is present. Therapy can be stepped down from IV to oral antibiotics once the patient is clinically improving and can tolerate oral intake.

Local and Supportive Care

• Elevation of the affected limb to reduce edema and pain.
• Analgesia with acetaminophen or NSAIDs as appropriate.
• Treatment of portal of entry (e.g., topical antifungals for tinea pedis, appropriate wound care for ulcers).
• Hydration and management of comorbidities (e.g., glycemic control in diabetes).
• Marking the margins of erythema at presentation to track progress over 24–48 hours.

Complications

• Abscess formation requiring incision and drainage.
• Necrotizing soft tissue infection (necrotizing fasciitis) – a surgical emergency.
• Bacteremia and sepsis, especially in immunocompromised or elderly patients.
• Septic thrombophlebitis or deep vein thrombosis in affected limbs.
• Recurrent cellulitis, leading to progressive lymphatic damage and chronic lymphedema.

Prevention and Risk Factor Modification

• Management of chronic edema and lymphedema with compression therapy when appropriate.
• Treatment of tinea pedis and interdigital maceration to reduce portals of entry.
• Skin care education: moisturizers for dry skin, prompt care of minor wounds, avoidance of trauma.
• Weight reduction for obesity and optimization of glycemic control in diabetes.
• In patients with recurrent cellulitis (e.g., ≥3–4 episodes per year) despite optimized risk factor management, some guidelines support consideration of prophylactic low-dose oral penicillin for selected high-risk patients; this is typically specialist-guided.

Special Populations

• Pediatric patients: Present similarly but require weight-based antibiotic dosing and attention to immunization status and atypical exposures; complex regional pain syndrome can rarely develop after painful limb conditions and should be recognized early in pediatric practice. [6](https://europepmc.org/article/MED/41821844)
• Immunocompromised hosts: Broader empiric coverage may be needed, and unusual organisms should be considered; lower threshold for imaging and specialist consultation.
• Facial/periorbital cellulitis: Requires careful evaluation to differentiate preseptal from orbital cellulitis due to risk of orbital complications; sinus disease, trauma, and surgery are common sources, and orbital involvement can lead to serious sequelae. [2](https://europepmc.org/article/MED/41815776)

Key Clinical Pearls

• Cellulitis is primarily a clinical diagnosis; labs and imaging assist in assessing severity and excluding alternatives rather than confirming cellulitis.
• Distinguish non-purulent from purulent infection to guide streptococcal vs MRSA-targeted empiric therapy.
• Always search carefully for a portal of entry (e.g., tinea pedis, ulcers, trauma) and treat it to reduce recurrence.
• Marking the borders of erythema at presentation is a simple and effective way to follow response to therapy over the first 24–48 hours.
• Consider necrotizing infection when pain is disproportionate, progression is rapid, or bullae, skin necrosis, crepitus, or systemic toxicity are present; this warrants immediate surgical evaluation.
• Many conditions mimic cellulitis (stasis dermatitis, DVT, gout, contact dermatitis); repeated “cellulitis” not responding to appropriate antibiotics should prompt reconsideration of the diagnosis.
• In patients with recurrent cellulitis, aggressively address underlying edema, venous disease, and skin barrier disorders; consider prophylactic antibiotics only after optimizing modifiable factors.
• In children and in facial/periorbital infections, early recognition and appropriate imaging/consultation help prevent serious orbital and neurologic complications. [2](https://europepmc.org/article/MED/41815776) [6](https://europepmc.org/article/MED/41821844)

Exam Tips for Medical Students

• On exams, non-purulent lower leg cellulitis after tinea pedis or trauma in a patient with chronic edema typically points to streptococcal infection treated with a β-lactam (e.g., cephalexin or cefazolin).
• Purulent lesions, history of MRSA, or abscess should trigger consideration of MRSA coverage (TMP-SMX, doxycycline, clindamycin, or vancomycin depending on severity).
• Pain out of proportion to exam, crepitus, or bullae suggests necrotizing fasciitis, not simple cellulitis.
• In recurrent cellulitis with chronic lymphedema, consider prophylactic penicillin after risk factor optimization as a high-yield concept.
• Be comfortable differentiating cellulitis from erysipelas (superficial, sharply demarcated) and DVT (swelling and pain but usually less erythema and systemic inflammatory signs).

Summary

Cellulitis is a common, clinically diagnosed bacterial infection of the dermis and subcutaneous tissue, usually due to β-hemolytic streptococci and Staphylococcus aureus. Accurate recognition, appropriate empiric antibiotic selection, identification of red flags for deeper or necrotizing infection, and targeted management of underlying risk factors are essential to reduce morbidity, prevent recurrence, and optimize patient outcomes. Understanding the clinical nuances and differential diagnosis is crucial for medical students preparing for examinations and for clinical practice.